

Freedom of Information Request: Our Reference CTHB_298_19

You asked:

Within your Health Board how many of the following intra-vitreous vials/implants have been used in the latest 4 months, if possible between May to August 2019; for the following eye conditions;

	Ranibizumab	Bevacizumab	Aflibercept	Fluocinolone	Dexamethasone
Wet Age Related Macular Degeneration (wAMD)	380		461		
Diabetic Macular Oedema (DMO)	107		211		7
Retinal Vein Occlusion – Central or Branch (CRVO or BRVO)	104		114		**
Other eg mCNV	5	21	9		**

Our response:

In response to your recent request the table above has been populated with the number of injections administered during the period of 1st May and 31st August 2019, by medicine and by diagnosed eye condition.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.